Aptevo Therapeutics Profit Margin 2014-2021 | APVO
Current and historical gross margin, operating margin and net profit margin for Aptevo Therapeutics (APVO) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Aptevo Therapeutics net profit margin as of September 30, 2021 is -265.8%.
| Aptevo Therapeutics Annual Profit Margins |
| Aptevo Therapeutics Quarterly Profit Margins |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.043B |
$0.004B |
|
Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.
|
